Burden of illness and treatment attitudes among participants meeting Rome IV criteria for irritable bowel syndrome: A nationwide survey in the United States.

Autor: Lacy BE; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA., Xu Y; AbbVie Inc, North Chicago, Illinois, USA., Taylor DCA; Former employee of Ironwood Pharmaceuticals, Boston, Massachusetts, USA., Kosch KJ; AbbVie Inc, North Chicago, Illinois, USA., Dobrescu R; Acumen Health Research Institute, Ann Arbor, Michigan, USA., Morlock A; Acumen Health Research Institute, Ann Arbor, Michigan, USA., Morlock R; YourCareChoice, Ann Arbor, Michigan, USA., Rooker C; International Foundation for Gastrointestinal Disorders, Milwaukee, Wisconsin, USA.
Jazyk: angličtina
Zdroj: Neurogastroenterology and motility [Neurogastroenterol Motil] 2024 Nov; Vol. 36 (11), pp. e14903. Date of Electronic Publication: 2024 Sep 02.
DOI: 10.1111/nmo.14903
Abstrakt: Background: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by abdominal pain and altered bowel habits, with patient-perceived dissatisfaction of treatment symptom control. We assessed disease burden, satisfaction with medication use, and impact on activities, in participants with IBS with constipation (IBS-C) and diarrhea (IBS-D).
Methods: This study assessed data from a large, United States survey of adults querying demographics, comorbid conditions, quality of life, medication use, satisfaction with symptom control, and work productivity. Participants were grouped into the IBS-C or IBS-D cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self-reported.
Key Results: Nine hundred and ten participants with IBS-C and 669 with IBS-D were matched to controls. The most reported symptoms were abdominal discomfort for IBS-C and abdominal pain and abdominal discomfort for IBS-D. Among the IBS-C and IBS-D cohorts, 74.2% and 65.9%, respectively, took prescription and/or over-the-counter medication for their symptoms. Respondents were more dissatisfied than satisfied with control of their symptoms. Respondents taking prescription medication(s) with or without over-the-counter medication(s) reported better symptom control than respondents only taking over-the-counter medications (p < 0.001). There was significantly higher mean presenteeism, work productivity loss, and daily activity impairment (p < 0.001 for all) in respondents with IBS compared with controls.
Conclusions and Inferences: This study provides insight into respondents' experiences of IBS symptoms, including the impact on daily activity, as well as satisfaction with control of symptoms and prescription and over-the-counter medications.
(© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: